RBC Capital Initiates Coverage on Rigel Pharmaceuticals (RIGL) with an Outperform
More News related to RIGL
- Rigel Announces Third Quarter 2009 Financial Results
- Rigel Announces Presentations at Two Investor Conferences
- Rigel to Webcast Analyst Briefing on October 20, 2009
- Rigel Pharma (RIGL) Prices 13M Shares at $7.25
- Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
More News related to New Coverage
- Sidoti & Co Initiates Coverage on Stratasys (SSYS) with a Neutral
- ThinkEquity Initiates Coverage on Sourcefire (FIRE) with a Buy
- Raymond James Initiates Coverage on Knight Capital (NITE) with a Market Perform
- Raymond James Initiates Coverage on International Game Technology (IGT) with a Market Perform
- Thomas Weisel Initiates Coverage on UQM Technologies (UQM) with an Overweight
RBC Capital initiates coverage on Rigel Pharmaceuticals (Nasdaq: RIGL) with an Outperform. Price target $31.
Rigel Pharmaceuticals, Inc. (Rigel) is a clinical-stage drug development company that discovers and develops small molecule drugs for the treatment of inflammatory/autoimmune diseases, cancer and viral diseases.
Related Categories
New CoverageStocks Mentioned
-0.41Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
